year 17, Issue 3 (May - June 2023)                   Iran J Med Microbiol 2023, 17(3): 354-360 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Aziz L M, Alhachami F R, Abdullah M A, S. Abed A, Hassib Ali M, Al-Yasiri R M, et al . Molecular Characterization and Antibiotic Resistance Profile of Staphylococcus haemolyticus in Pregnant Women with Urinary Tract Infections. Iran J Med Microbiol 2023; 17 (3) :354-360
URL: http://ijmm.ir/article-1-2131-en.html
1- Department of Biotechnology, College of Applied Sciences, University of Fallujah, Iraq
2- Department of Biology, College of Education for Pure Science, Wasit University, Wasit, Iraq
3- Department of Microbiology, Ninevah College of Medicine, Ninevah University, Mosul, Iraq
4- Jabir Ibn Hayyan University of Medical and Pharmaceutical Sciences, Najaf, Iraq
5- Dhi-Qar Health Directorate, Iraqi Ministry of Health, Nasiriya, Iraq
6- Alshaheed fayrooz hospital, Wasit Health Directorate, Iraqi Ministry of Health, Wasit, Iraq
7- College of Pharmacy, National University of Science and Technology, Dhi Qar, Iraq , qiasqiasqias@gmail.com
Full-Text [PDF 597 kb]   (804 Downloads)     |   Abstract (HTML)  (2725 Views)
Full-Text:   (507 Views)
Introduction


Staphylococcus haemolyticus is a commonly encountered pathogen responsible for staphylococcal infections and is the predominant and clinically significant species among Coagulase-negative staphylococci (CoNS) (1-4). The rapid adaptation and development of antibiotic resistance, including methicillin resistance, and its ability to persist in healthcare settings underscore the significance of multi-resistance in assessing the risk posed by this pathogen (5-7). Methicillin-resistant S. haemolyticus isolates have been associated with sepsis and increased patient morbidity and mortality rates, thus emphasizing the clinical impact of antibiotic resistance (8-10). Moreover, S. haemolyticus demonstrates remarkable versatility and adaptability within the hospital environment and medical devices, making it a key contributor to nosocomial infections (11, 12).
Staphylococcus haemolyticus is frequently isolated from human urine and wound swab cultures, ranking second only to Staphylococcus epidermidis among CoNS species. It plays a pivotal role in healthcare-associated opportunistic infections, particularly those related to implanted medical devices. Among CoNS, S. haemolyticus exhibits the highest level of antibiotic resistance, with common heteroresistance to glycopeptides (13-15). Its capacity to develop biofilms and colonize hospital environments further contributes to its persistence and pathogenicity, leading to infections such as endocarditis, urinary tract infections, septicemia, and peritonitis. The genome of S. haemolyticus encodes enzymes involved in forming the polygamma-glutamate capsule, which provides defense against cationic antimicrobial peptides (1, 16, 17).
Staphylococcal hemolysins, classified into four toxin types (alpha, beta, gamma, and delta), play a significant role in the virulence of S. haemolyticus. The hla gene, encoding a pore-forming cytotoxin (PFT), targets various human cell types and acts as a detergent on erythrocytes. Another notable feature of S. haemolyticus is its capacity to form biofilms. Bacterial exopolysaccharides generated during biofilm formation may restrict growth and promote the formation of structured biofilms (18-20). Additionally, fibronectin, a glycoprotein found in host tissues, facilitates adhesion between Staphylococcus aureus cells and host cells, playing a crucial role in eukaryotic cell adhesion (21, 22).
This study aimed to investigate antibiotic sensitivity, biofilm formation capabilities, and the presence of virulence-associated genes (hla, hlb, fnbA, and fnbB) in S. haemolyticus isolates. Our study uniquely focuses on pregnant women with urinary tract infections caused by S. haemolyticus. Employing a comprehensive approach, including molecular characterization, antibiotic resistance profiling, and assessment of virulence factors and biofilm formation, we sought to provide accurate insights into the pathogenicity and antimicrobial resistance mechanisms of S. haemolyticus. By addressing these research gaps, our study contributes valuable knowledge to the field, enabling the development of tailored prevention and treatment strategies for this population.


 

Materials and Methods

This study was conducted in Al-Rifai General Hospital from October 2021 to December 2022 to isolate S. haemolyticus from clinical samples. The study obtained ethical approval from the Iraqi Ministry of Health. A total of 260 urine swab samples were cultured on CLED agar (Cystine Lactose Electrolyte-Deficient agar) obtained from (Oxoid, Ltd., Basingstoke, Hampshire, England). The suspected S. haemolyticus isolates were subjected to mannitol fermentation, catalase, and coagulase tests followed by API staph identification. Further confirmation of identification was conducted using the VITEK-2 system. Antibiotic sensitivity testing was also conducted using the VITEK-2 system with relevant cards to confirm the susceptibility patterns of isolated S. haemolyticus strains against different antibiotics. Semi-quantitative determination of biofilm formation was carried out following the microtiter plate assay method.
The biofilm production assay was performed using the microtiter plate method. Overnight cultures of S. haemolyticus isolates were diluted in tryptic soy broth supplemented with glucose and added to 96-well microtiter plates. After 24 hours of incubation at 37°C, non-adherent cells were removed by washing, and the biofilms were fixed with methanol and stained with crystal violet. OD570 values were measured after solubilizing the stain with acetic acid. Biofilm production was categorized as negative (OD570 ≤ 0.1), weak (0.1 < OD570 ≤ 0.5), or strong (OD570 > 0.5) based on the optical density values.
The DNA was extracted from S. haemolyticus isolates using the PrestoTM Mini gDNA Bacteria Kit Quick Protocol (Geneaid), and PCR amplification was performed to detect the presence of virulence-associated genes (hla, hlb, fnbA, and fnbB) in the S. haemolyticus isolates. The primer sequences used for the amplification of each gene as well as the expected PCR product size are included in Table 1. Moreover, Table 2 provides details of the PCR cycling parameters and conditions used to detect these genes.

 
Table 1. The primer sequences and expected PCR product size of each gene

The gene The primer sequences Expected PCR product size
hla Forward primer: 5'-ATGAAAAAGCCTGAAAGAA-3'
Reverse primer: 5'-TTATTTTACATCCATACTTATG-3'
800 base pairs
hlb Forward primer: 5'-TCTAATGATTTGACTAAAGT-3'
Reverse primer: 5'-TTACTTATTTTATGTTTGGT-3'
900 base pairs
fnbA Forward primer: 5'-ATGAAAAAGCCTGAAAGAA-3'
Reverse primer: 5'-TTATTTTACATCCATACTTATG-3'
1000 base pairs
fnbB Forward primer: 5'-TCTAATGATTTGACTAAAGT-3'
Reverse primer: 5'-TTACTTATTTTATGTTTGGT-3'
1200 base pairs


Table 2. PCR Cycling Parameters and Conditions

PCR steps Temp. Time Repeat
Initial Denaturation 95 °C 5min 1 cycle
Denaturation 95 °C 30sec. 1 cycle
Annealing 55 °C a, b 30sec. 38 cycles
Extension 72 °C 1 min. 1 cycle
Final extension 72 °C 5min. 1 cycle

 
 

Results

In this study, a total of 260 clinical samples were tested, from which 36 S. haemolyticus isolates were identified. The antibiotic resistance profile of these isolates was assessed as illustrated in Figure 1, revealing a high level of resistance to multiple antibiotics. The isolates demonstrated complete resistance to Benzylpenicillin (100%) and high resistance rates to Erythromycin (88.8%), Oxacillin (80.55%), Trimethoprim/ sulfamethoxazole (80.55%), Levofloxacin (72.22%), and Gentamicin (55.55%). On the other hand, lower resistance rates were observed for Tigecycline (0%), Linezolid (11.11%), Tobramycin (27.77%), Rifampin (36.11%), Vancomycin (36.11%), Moxifloxacin (41.66%), Tetracycline (44.44%), and Ticoplanin (52.77%). Statistical evaluation of antibiotic resistance demonstrated a significant difference (p=0.0001) between resistant and sensitive isolates for all tested antibiotics, except for Moxifloxacin, where no significant difference (p > 0.05) was observed.

 
 Figure 1. Antibiotic Resistance Profile of S. haemolyticus Isolates, where TIC= Ticoplanin, TET= Tetracycline, MOX= Moxifloxacin, VAN= Vancomycin, RIF= Rifampin, TOB= Tobramycin, LIN= Linezolid, TRI= Tigecycline, GEN= Gentamicin, LEV= Levofloxacin, TRI/SUL= Trimethoprim/sulfamethoxazole, OXA= Oxacillin, ERY= Erythromycin, and BEN= Benzylpencillin
Figure 1. Antibiotic Resistance Profile of S. haemolyticus Isolates, where TIC= Ticoplanin, TET= Tetracycline, MOX= Moxifloxacin, VAN= Vancomycin, RIF= Rifampin, TOB= Tobramycin, LIN= Linezolid, TRI= Tigecycline, GEN= Gentamicin, LEV= Levofloxacin, TRI/SUL= Trimethoprim/sulfamethoxazole, OXA= Oxacillin, ERY= Erythromycin, and BEN= Benzylpencillin

Furthermore, this study investigates the biofilm formation capabilities of S. haemolyticus and explore the presence of virulence-associated genes. The analysis revealed a PIA-independent biofilm formation in S. haemolyticus, distinguishing it from ica-negative isolates. Among the 36 isolates tested, 25 (69.4%) were found to be negative for biofilm formation, while 11 (30.6%) showed weak biofilm formation. No isolates exhibited strong biofilm formation. Notably, all 36 isolates demonstrated the presence of the α-hemolysin gene (hla), while the β-hemolysin gene (hlb) was detected in 28 out of 36 isolates, representing 77.7% of the samples, as determined through PCR analysis. Additionally, the prevalence of Fibronectin A (fnbA) and B (fnbB) genes was observed in 88.8% and 38.8% of the isolates, respectively, as shown in Table 3. To further corroborate these findings, gel electrophoresis was employed, visually confirming the amplified presence of these virulence-associated genes (Figure 2: (a) fnbB gene, (b) fnbA gene, (c) hla gene, and (d) hlb gene).


Table 3. Presence and Absence of Genes in the Samples

Gene No. of samples No. of positive samples No of negative sample Percentage of sample positive
α-Hemolysin 36 36 0 100 %
ß-Hemolysin 36 28 8 77.7 %
Fibronectin-Binding Proteins A 36 32 4 88.8 %
Fibronectin-Binding Proteins B 36 14 22 38.8 %
Chi-Square: χ2
(P-value)
--- --- --- 10.372 **
(0.00982)

** (P≤0.01)-Highly Significant.
 

 Figure 2. Gel electrophoresis of (a) fnbB gene, (b) fnbA gene, (c) hla gene, and (d) hlb gene in S. haemolyticus
Figure 2. Gel electrophoresis of (a) fnbB gene, (b) fnbA gene, (c) hla gene, and (d) hlb gene in S. haemolyticus

 

Moreover, Table 4 presents the types of drug resistance observed in the S. haemolyticus isolates. Multiple drug resistance (MDR) was highly prevalent, accounting for 91.7% of the isolates. Three isolates (8.3%) exhibited extensive drug resistance (XDR). No isolates showed pan drug resistance (PDR). To determine these resistance patterns, we assessed the susceptibility of S. haemolyticus isolates against a panel of different antibiotics using the VITEK-2 system. The isolates that showed resistance to two or more classes of antibiotics were classified as MDR, while those resistant to nearly all but two or fewer antimicrobial categories were classified as XDR. Isolates that displayed resistance to all agents in all antimicrobial categories were classified as PDR.


Table 4. Types of Drug Resistance in S. haemolyticus Isolates

Type of resistance No. of isolates Percentage of sample (%)
DR 0 0
MDR 33 91.7
XDR 3 8.3
PDR 0 0
Total 36 100

DR=drug resistance, MDR=Multiple drug resistance, XRD=Extensive Drug Resistance, PDR= Pan drug resistance

 
 

Discussion

The current study revealed a high level of antibiotic resistance among S. haemolyticus isolates, with multiple antibiotics showing high resistance rates. Complete resistance was observed for Benzylpenicillin, followed by high resistance rates for Erythromycin, Oxacillin, Trimethoprim/ sulfamethoxazole, Levofloxacin, and Gentamicin. These findings are consistent with previous studies (23, 24) and suggest that S. haemolyticus has become increasingly resistant to multiple antibiotics.
Sing et al. reported a lower resistance rate to Erythromycin (17%) in their S. haemolyticus isolates (25). On the other hand, Tigecycline, Linezolid, Tobramycin, Rifampin, Vancomycin, Moxifloxacin, Tetracycline, and Ticoplanin showed lower resistance rates in this study compared to previous reports. However, an Iraqi research study reported a Linezolid resistance rate of 4.35% among S. haemolyticus isolates (26). The rising resistance to Linezolid raises concerns, as it is frequently used for gram-positive cocci infections (23). Resistance to Linezolid may be caused by mutations in the cfr or 23S rRNA gene (24). Whole-genome sequencing revealed the remarkable genomic flexibility and phenotypic acquisition of antibiotic resistance in S. haemolyticus (25).
In our study, Tigecycline, a glycylcycline antibiotic, showed complete sensitivity, consistent with previous findings (27). Additionally, combining Tigecycline with Rifampin has been found to have a strong impact on biofilm-forming S. haemolyticus (28). This suggests that Tigecycline, alone or in combination with other antibiotics, could be a potential treatment option for S. haemolyticus infections. Statistical analysis of antibiotic resistance revealed a significant difference (p=0.0001) between resistant and sensitive isolates for all tested antibiotics, except for Moxifloxacin, where no significant difference (p > 0.05) was observed. This indicates that the observed resistance patterns are not due to chance.
Biofilm formation in S. haemolyticus appears to be Polysaccharide Intercellular Adhesin (PIA)-independent, as biofilm formation has been reported in ica-negative isolates. Similar research conducted by (29) has shown that S. haemolyticus and other staphylococci isolated from community contexts lacked the icaAD and bap genes (30). These findings suggest alternative mechanisms may be responsible for biofilm formation in S. haemolyticus strains.
The presence of the α-hemolysin gene (hla) was detected in all 36 S. haemolyticus isolates, while the β-hemolysin gene (hlb) was present in 28 out of 36 isolates. This indicates a high prevalence of these hemolysin genes in S. haemolyticus strains, which may contribute to their virulence. The presence of Fibronectin A (fnbA) and B (fnbB) genes in S. haemolyticus isolates suggests that fibronectin-binding proteins may play a role in bacterial attachment to surfaces and biofilm formation.
The high prevalence of multiple drug resistance (MDR) among S. haemolyticus isolates is consistent with previous studies (29, 31). The widespread use of antimicrobial agents, acquisition of mobile genetic elements, genomic rearrangements, and mutations are factors that contribute to the emergence of antibiotic resistance in S. haemolyticus. The resistance to Vancomycin and Linezolid is particularly concerning, which highlights the clinical impact of S. haemolyticus, especially as methicillin-resistant strains have become common nosocomial pathogens (32). It is imperative to address the challenge of antibiotic resistance in S. haemolyticus for effective infection control in healthcare settings (30).


 

Conclusion

In conclusion, this study sheds light on the pathogenicity and antimicrobial resistance of Staphylococcus haemolyticus. The isolates exhibited high resistance rates to various antibiotics, with complete resistance to Benzylpenicillin and concerning trends in Linezolid resistance. The presence of virulence-associated genes, including hla and fibronectin-binding proteins fnbA and fnbB, underscores their potential role in the pathogenicity of S. haemolyticus. Biofilm formation appears to be PIA-independent. The prevalence of multiple drug resistance (MDR) highlights the urgent need for effective infection control in healthcare settings. This research provides valuable data for tailored prevention and treatment strategies, contributing to the understanding and managing S. haemolyticus infections.

 

Acknowledgment

'Not applicable.’

 

Funding

'Not applicable.’

 

Conflicts of Interest

The authors declare no conflict of interest.
 

 

Type of Study: Original Research Article | Subject: Molecular Microbiology
Received: 2023/06/10 | Accepted: 2023/07/20 | ePublished: 2023/07/26

References
1. Jasim EM, Jameel SK, Awadh NI. Evaluation of Urinary Tract Infection and Measurement of Interleukin 18 in Iraqi Patients with Rheumatoid Arthritis. J Med Chem Sci. 2023; 6(2):440-8.
2. Michalik M, Samet A, Podbielska-Kubera A, Savini V, Międzobrodzki J, Kosecka-Strojek M. Coagulase-negative staphylococci (CoNS) as a significant etiological factor of laryngological infections: A review. Ann Clin Microbiol Antimicrob. 2020;19(1): 1-10. [DOI:10.1186/s12941-020-00367-x] [PMID] [PMCID]
3. Lotfi H, Khalilzadeh T, Damchi M, Hassan M. Biocides Susceptibility of Clinically Isolated Escherichia coli in Presence and Without Organic Material. Iran J Med Microbiol 2022;16(5):447-56. [DOI:10.30699/ijmm.16.5.447]
4. Koupahi H, Honarmand Jahromy S, Mardani M, Khodadadi E, Rahbar M, Eslami P, et al. Detection of Methicillin Resistant Staphylococcus aureus (MRSA) by CHROMagar Versus Cefoxitin Disk Diffusion Method. Iran J Med Microbiol. 2023; 17(2):251-5. [DOI:10.30699/ijmm.17.2.251]
5. Al-Rawi SSM, Salahdin OD, Al-Alaq FT, Abdulazeem LH, Kzar M, Shawky Khattab E, et al. Antibacterial Activity of Bacteriocin - Isolated from Lactobacillus Spp. Against Some Pathogenic Bacteria. J Med Chem Sci. 2023;6(4):702-9.
6. Al-Shalah LAM, Hadi BH, Abood FMK, Hindi NK, Hamza SA, Jasim AN, et al. Antibacterial Effect of Aqueous Extract of Theobroma Cacao Against Gram-Negative and Gram-Positive Bacteria: An in Vitro Study. J Med Chem Sci. 2023;6(3):464-471.
7. Miragaia M. Factors contributing to the evolution of mecA-mediated β-lactam resistance in staphylococci: update and new insights from whole genome sequencing (WGS). Front Microbiol. 2018; 9:2723. [DOI:10.3389/fmicb.2018.02723] [PMID] [PMCID]
8. Chaudhry V, Patil PB. Evolutionary insights into adaptation of Staphylococcus haemolyticus to human and non-human niches. Genomics. 2020; 112(2):2052-62. [DOI:10.1016/j.ygeno.2019.11.018] [PMID]
9. Mahdi MH, Dawood AH, Shaheed DQ. Synthesis and study of antimicrobial activity of some tetrahydrocarbazole derivatives substituted with NSAID. Al-Mustansir J Pharm Sci 2022;22(2):44-54. [DOI:10.32947/ajps.v22i2.857]
10. Fateh Dizji P, Khosravy M, Saeedi AA, Asli M, Sepahvand S, Darvishi M. Prevalence of Clindamycin-resistant Staphylococcus aureus Induced by Macrolide Resistance, Iran, 2019-2021. Iran J Med Microbiol. 2023;17(2):256-61. [DOI:10.30699/ijmm.17.2.256]
11. Al-Ani FW, Fahad HM. Estimation of Activity of CD14 Biomarker in Iraqi Burn Patients. J Med Chem Sci. 2023;6(2):313-21.
12. Alhusain MTA, Jaafar FN, Hassan AAA. Isolation and characterization of Staphylococcus haemolyticus from urinary tract infection. EurAsian J Biosci. 2020;14(1):1909-13.
13. Abdalrazaq Ibrahem R, F. N. Al.Zobadyi S. Synthesis of New β-Lactam, Tetrazole, Thiazolidinone, and Oxazepine Compounds from Schiff Bases and Study of Their Biological Activity. J Med Chem Sci. 2023; 6(3):480-5.
14. Asante J, Amoako DG, Abia AL, Somboro AM, Govinden U, Bester LA, et al. Review of clinically and epidemiologically relevant coagulase-negative staphylococci in Africa. Microb Drug Resist. 2020; 26(8):951-70. [DOI:10.1089/mdr.2019.0381] [PMID]
15. Latief BH, Ismail RH, Hamzah BF, Husseini MD, Khudhair NA. Antibacterial and Anticorrosion Activity Evaluation of New Polymaleimide Derived from Chalcone Derivative. J Med Chem Sci. 2023; 6(4):755-63.
16. Musafer H, Al-Bayati M, Kareem S. Epidemiology and Genetic Diversity of CTX-M Gene in Klebsiella Pneumoniaein Baghdad City. J Med Chem Sci. 2022;6(6):1419-25.
17. Dos Santos G, Solidônio E, Costa M, Melo R, de Souza I, Silva G, et al. Study of the Enterobacteriaceae Group CESP (Citrobacter, Enterobacter, Serratia, Providencia, Morganella and Hafnia): A Review. The Battle Against Microbial Pathogens: Basic Science, Technological Advances and Educational Programs (A Méndez-Vilas, Ed) FORMATEX. 2015:794-805.
18. Askari F, Davoodi M, Ghelichli M, Asadi I, Jazideh F. The preventive effects of silymarine extract against Streptococcus mutans virulence and caries development in rat model and in vitro condition. Eurasian Chem Commun. 2020;2(12):1164-71.
19. Rossi C, Santos‐Gandelman J, Barros E, Alvarez V, Laport M, Giambiagi‐deMarval M. Staphylococcus haemolyticus as a potential producer of biosurfactants with antimicrobial, anti‐adhesive and synergistic properties. Lett Appl Microbiol. 2016;63(3):215-21. [DOI:10.1111/lam.12611] [PMID]
20. Yaseen MM, Alkubaisy SA, Mohammad WT, Jalil AT, Dilfy SH. Cancer and Complications of Peptic Ulcer in Type 2 Diabetes Mellitus patients at Wasit province, Iraq. J Med Chem Sci. 2023;6(2):335-45.
21. Abid TS, Aowda S, Drea AA. New Resorcinol Derivatives: Preparation, Characterization and Theoretical Investigation. J Med Chem Sci. 2023; 6(5):962-9.
22. Speziale P, Pietrocola G. The multivalent role of fibronectin-binding proteins A and B (FnBPA and FnBPB) of Staphylococcus aureus in host infections. Front Microbiol. 2020;11:2054. [DOI:10.3389/fmicb.2020.02054] [PMID] [PMCID]
23. Abbasi Montazeri E, Seyed-Mohammadi S, Asarehzadegan Dezfuli A, Khosravi AD, Dastoorpoor M, Roointan M, et al. Investigation of SCC mec types I-IV in clinical isolates of methicillin-resistant coagulase-negative staphylococci in Ahvaz, Southwest Iran. Biosci Rep. 2020;40(5): BSR20200847. [DOI:10.1042/BSR20200847] [PMID] [PMCID]
24. Kitti T, Seng R, Saiprom N, Thummeepak R, Chantratita N, Boonlao C, et al. Molecular characteristics of methicillin-resistant staphylococci clinical isolates from a tertiary Hospital in Northern Thailand. Can J Infect Dis Med Microbiol. 2018;2018. [DOI:10.1155/2018/8457012] [PMID] [PMCID]
25. Singh L, Cariappa M, Das N. Drug sensitivity pattern of various Staphylococcus species isolated at a tertiary care hospital. Med J Armed Forces India. 2016;72:S62-S6. [DOI:10.1016/j.mjafi.2016.07.009] [PMID] [PMCID]
26. Kalinka J, Hachmeister M, Geraci J, Sordelli D, Hansen U, Niemann S, et al. Staphylococcus aureus isolates from chronic osteomyelitis are characterized by high host cell invasion and intracellular adaptation, but still induce inflammation. Inter J Med Microbiol. 2014;304(8): 1038-49. [DOI:10.1016/j.ijmm.2014.07.013] [PMID]
27. Pinheiro L, Brito CI, Pereira VC, Oliveira A, Bartolomeu AR, Camargo CH, et al. Susceptibility profile of Staphylococcus epidermidis and Staphylococcus haemolyticus isolated from blood cultures to vancomycin and novel antimicrobial drugs over a period of 12 years. Microb Drug Resist. 2016;22(4):283-93. [DOI:10.1089/mdr.2015.0064] [PMID]
28. Szczuka E, Krajewska M, Lijewska D, Bosacka K, Kaznowski A. Diversity of staphylococcal cassette chromosome mec elements in nosocomial multiresistant Staphylococcus haemolyticus isolates. J Appl Genet. 2016;57:543-7. [DOI:10.1007/s13353-016-0346-5] [PMID] [PMCID]
29. Seng R, Kitti T, Thummeepak R, Kongthai P, Leungtongkam U, Wannalerdsakun S, et al. Biofilm formation of methicillin-resistant coagulase negative staphylococci (MR-CoNS) isolated from community and hospital environments. PloS one. 2017;12(8):e0184172. [DOI:10.1371/journal.pone.0184172] [PMID] [PMCID]
30. Kitti T, Seng R, Thummeepak R, Boonlao C, Jindayok T, Sitthisak S. Biofilm formation of methicillin-resistant coagulase-negative Staphylococci isolated from clinical samples in Northern Thailand. J Glob Infect Dis. 2019;11(3): 112. [DOI:10.4103/jgid.jgid_118_18] [PMID] [PMCID]
31. Wolden R, Pain M, Karlsson R, Karlsson A, Aarag Fredheim EG, Cavanagh JP. Identification of surface proteins in a clinical Staphylococcus haemolyticus isolate by bacterial surface shaving. BMC Microbiology. 2020;20(1):1-18. [DOI:10.1186/s12866-020-01778-8] [PMID] [PMCID]
32. Becker A. Challenges and perspectives in combinatorial assembly of novel exopolysaccharide biosynthesis pathways. Front Microbiol. 2015;6:687. [DOI:10.3389/fmicb.2015.00687] [PMID] [PMCID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Iranian Journal of Medical Microbiology

Designed & Developed by : Yektaweb | Publisher: Farname Inc